Skip to main content

Pharmacokinetics of inhaled colistin in critically ill patients with ventilator-associated tracheobronchitis


Although inhaled colistin is frequently used in ventilator-associated pneumonia (VAP), data regarding its pharmacokinetic properties are scarce [13]. The aim of this study was to describe colistin pharmacokinetics in critically ill patients after administration of a single dose of 1 million units of colistimethate sodium (CMS) via nebulization.


Patients with ventilator-associated tracheobronchitis dye to polymyxin-only susceptible Gram-negative bacteria were included in the study; patients receiving intravenous and/or nebulized colistin were excluded. CMS was administered at a dose of 1 million units every 8 hours for 7 days, via a vibrating-mesh nebulizer. Mini bronchoalveolar lavage was collected before and at 1, 4 and 8 hours post nebulization, while blood samples were collected before and at 0.16, 0.5, 1, 2, 4, and 8 hours post nebulization. Colistin concentrations in epithelial lining fluid (ELF) and plasma were determined by high-performance liquid chromatography.


Our study population included five patients (three female) with mean age 60.6 years. Median (range) colistin concentrations in ELF were 6.9 (6.2 to 13.9), 3.7 (2.7 to 11.6) and 2.1 (1.2 to 8.7) g/ml at 1, 4, and 8 hours, respectively, after nebulization. Colistin concentrations in serum were substantially lower than those observed in ELF with peak median (range) values 1.56 (1.19 to 2) g/ml. The estimated colistin mean half-life was 3.4 hours.


Administration of 1 million units of inhaled CMS resulted in high colistin concentrations in the ELF; moreover, concentrations were maintained for up to 8 hours in the majority of patients. This finding might support the use of inhaled CMS for the treatment of patients with VAP due to multidrug-resistant Gram-negative bacteria. Moreover, the low serum concentrations and the short half-life suggest that administration of inhaled colistin may be associated with less systemic toxicity.


  1. Ratjen F, et al.: J Antimicrob Chemother. 2006, 57: 306-311. 10.1093/jac/dki461

    CAS  Article  PubMed  Google Scholar 

  2. Marchand S, et al.: Antimicrob Agents Chemother. 2010, 54: 3702-3707. 10.1128/AAC.00411-10

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  3. Lu Q, et al.: Intensive Care Med. 2010, 36: 1147-1155. 10.1007/s00134-010-1879-4

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations


Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Cite this article

Athanassa, Z., Fousteri, M., Markantonis, S. et al. Pharmacokinetics of inhaled colistin in critically ill patients with ventilator-associated tracheobronchitis. Crit Care 16 (Suppl 1), P70 (2012).

Download citation

  • Published:

  • DOI:


  • Bronchoalveolar Lavage
  • Colistin
  • Epithelial Line Fluid
  • Peak Median
  • Colistimethate